Allergen immunotherapy for IgE-mediated food allergy: Protocol for a systematic review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated food allergy. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in IgE-mediated food allergy. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised. Discussion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 24 |
| Tidsskrift | Clinical and Translational Allergy |
| Vol/bind | 6 |
| Udgave nummer | 1 |
| ISSN | 2045-7022 |
| DOI | |
| Status | Udgivet - 5 jul. 2016 |
Bibliografisk note
Funding Information:
S. Dhami: support to undertake the systematic review; U. Nurmatov: support to undertake the review; Giovanni Pajno: none; Montserrat Fernandez‑Rivas: Participation in immunotherapy clinical trials sponsored by ALK‑Abello; A. Muraro: Acting in consulting capacity for ALK, Meda Pharma, Nestle, Nutricia, Novartis. Grants from: Nestlé: Co‑investigator for research protocol, Nutricia: Co‑investigator for research protocols; G. Roberts: Materials for research programme (ALK‑Abello), research grant (ALK‑Abello), advisory board (ALK‑ Abello), speaker (Allergy Therapeutics, ALK‑Abelo); C. Akdis: consulting fee Novartis, Boehringer‑Ingelheim; stocks Davos Diagnostics, Allimentary Health Pharma Davos; research grant Novartis, Allergopharma; M. Alvaro‑Lozano: none; K. Beyer: European Union, German Research Foundation,Berliner Sparkasse, Danone, ThermoFisher Diagnostics, Foundation for the Treatment of Peanut Allergy, author of A European perspective on immunotherapy for food allergies; C. Bindslev‑Jensen: Grant from Hal Allergy. Consultancy for Hal Allergy; W Burks: none; G. du Toit: Equity in the FoodMaestro Application. Grants supporting the LEAP Study paid to Kings College, London. Author of the 2015 NEJM LEAP Study manuscripts that do not primarily deal with immunotherapy; M. Ebisawa: none; P. Eigenmann: Grants from LETI, Nestlé, ThermoFisher2, Consulting fee or honorarium from Danone, Novartis, ALK,DBV technologies, Stallergenes, Allergopharma; Edward Knol: Research grant for analysis modified peanut and cows milk allergens from HAL Allergy, Numico research. Consultancy fee from HAL Allergy, advice on peanut allergens; M. Makela: not known; K. Christine Nadeau: none; L. O’Mahony: Consultancy to Alimentary Health Ltd, a probiotic company; N. Papado‑ poulos: Grant from GSK, NESTLE, MERCK. Consulting fee from GSK, ABBVIE, Novartis, Menarini, Meda, AlK‑ABELLO, Allergopharma, Uriach, Stallergenes. Payment for development of educational presentations for Abbvie, Sanofi, Menarini & Meda; L. Poulsen: Grants for Clinical trials in collaboration with ALK, Stallergenes, BioMay, and Anergis; C. Sackesen: Funding from MSD to support laboratory tests for the study ‘Effects of the montelukast therapy on asthma and allergic inflammation in children with food allergy’; H. Sampson: received grants or other research support from NIAID; National Institutes of Health, published an editorial accompanying LEAP study publication; A. Santos: none; R. van Ree: Consultancy for HAL Allergy; F. Timmermans: none with respect to this study; A. Sheikh: support to co‑ordinate the undertaking of the systematic review and development of the guidelines.
Publisher Copyright:
© 2016 Dhami et al.
ID: 311565809